Bioavailability/bioequivalence focus group

The Bioavailability/Bioequivalence Focus Group (BA/BE FG) is part of FIP’s Special Interest Group on Regulatory Science. It aims to offer up-to-date information on BA/BE of oral drugs and to discuss the international harmonisation in regulating and controlling the quality of oral drug products.

The goals of the BA/BE FG are to:

  • Understand up-to-date science and technology relating to oral bioavailability of drugs for contributing to the development of effective and safe oral drug products.
  • Understand the current status of regulatory issues for oral drug products and proposing international standards.


The group organises international symposia on the bioavailability/bioequivalence of oral drug products (“Babe”). The first BABE symposium was held in Kobe, Japan, in 2011 and the second was in Seoul, Republic of Korea, in 2014. We’re currently working on our third BABE symposium, which will be held in Lisbon, Portugal, 11-12 October 2018. More information to come.


The group is chaired by Prof. Shinji Yamashita. For further information, email